Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer

Experimental Oncology

Volumn 31, Issue 4, 2009, Pages 231-236

  Timovska, Yu O ^a   Pivnyuk, V M ^a   Oliynichenko, G P ^b   Anikushko, M F ^b   Zachartseva, L M ^b   Chekhun, V F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Kiev City Oncological Hospital   (Ukraine)

Author keywords

Basal subtype; Breast cancer; Estrogen receptor; Her 2 neu positive subtype; Luminal subtype; Pathomorphological response; Progesterone receptor

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE COURSE; DISEASE FREE SURVIVAL; HISTOLOGY; HISTORY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RELAPSE; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 75149178212     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cufer T. Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guide-lines and/or Adjuvant. Ann Oncol 2008; Suppl 7: vii41-5.
2. Charchenko VP, Rozshkov NI. The Mammology. National mainual. Moscow: Geotag-media, 2009; 324 p. (In Russian).
3. Banerjee S, Reis-Filho J.S, Ashley S, et al. Basal-like brest carcinomas: clinical outcome and response to chemotherapy. J Cline Pathol 2006; 59: 729-35.
4. Keam B, Im SA, Kim HJ. Prognostic impact of clinico-pathological parameters breast cancer treated with neoadjuvant docetaxel chemotherapy: paradoxical features of the triple negative cancer. BMC Cancer 2007; 7: 203.
5. Darb-Esfahani S, Loibl S, Müller BM, et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11: R69.
6. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanism underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
7. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population - based study. Proc Natl Acad Sci USA 2003; 100:10393-8.
8. Gaedcke J, Traub F, Midle S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from brest cancer. Mod Pathol 2007; 20: 864-70.
9. Rasmussen BB, Regan MM, Lykkesfeld A, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary result from the BIG 1-98 randomised trial. Lancet Oncol 2008; 3: 11-2.
10. Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2008; 10: 1093-108.
11. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytoceratins in human breast carcinoma. J Pathol 2004; 203: 661-71.
12. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.
13. Kreike B, van Kouwehove M, Horling H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinoimas. Breast Cancer Res 2007; 9: R65.
14. Da Silva L, Clarke C, Lakhani SR. Demystifying basallike breast carcinomas. J Clin Pathol 2007; 60: 1328-32.
15. Klimenko SV, Zakhartzeva LM. The role of mutation statuse of the gene Her-2/neu in cells of breast cancer. Oncology 2007; 9: 175-8. (In Russian)
16. Zachartceva L, Dyatel M, Grigoruc A. The morphological diagnostic of breas cancer. Kiev: Morion, 2007: 68. (In Russian)